Phio Pharmaceuticals Corp. (PHIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on September 3, 2025. The company is a clinical-stage biopharmaceutical firm incorporated in Delaware, with its principal executive offices in King of Prussia, PA. The report discloses specific corporate events and clinical trial updates occurring on the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report focused on specific events rather than a periodic financial statement (such as a 10-K or 10-Q) containing comprehensive financial data.
Material Changes and Events
- Clinical Trial Progress: Patients are now being treated in the 5th cohort of the company's ongoing Phase 1b clinical trial for skin cancer.
- Conference Presentation: Phio is scheduled to present at the H.C. Wainwright 27th Annual Global Investment Conference, to be held from September 8-10, 2025.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of specific risks and contingencies beyond the standard disclosures inherent in clinical trial progression. The primary outlook provided is the advancement of the Phase 1b trial and the upcoming investor conference presentation.
Key Facts for Investor Verification
- Verify the specific indications and patient enrollment numbers for the 5th cohort of the Phase 1b skin cancer trial.
- Review the content of the press release (Exhibit 99.1) for details on the upcoming presentation at the H.C. Wainwright conference.
- Check subsequent filings (10-Q or 10-K) for the most recent financial position, cash runway, and burn rate, as this 8-K does not contain financial statements.